Updated ARC-20 data showed casdatifan activity as monotherapy and in combinations across treatment lines in advanced clear cell RCC.
News|Articles|March 24, 2026
Early Intervention and Individualization Are Key to Improving Kidney Cancer Outcomes
Author(s)Kyle Doherty
Fact checked by: Caroline Seymour, Nicole Canfora Lupo
Neil Mendhiratta, MD, MS, and Toni K. Choueiri, MD, discuss the current and future treatment landscape of kidney cancer during Kidney Cancer Awareness Month.
Advertisement
Advertisement
Although the incidence of kidney cancer has stabilized after decades of increase with mortality rates on the decline, an emphasis on early intervention and treatment personalization is needed to maintain and build upon these improved outcomes for patients, according to Neil Mendhiratta, MD, MS.1
Related to this article
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Patients with resected RCC given adjuvant durvalumab with or without tremelimumab described persistent low-grade toxicities as most disruptive to QOL.
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.
The European Commission approved pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, irrespective of cisplatin eligibility.
Advertisement
Advertisement